LINK Completes Second Acquisition From Pfizer

by / Tuesday, 12 July 2005 / Published in News

LINK Pharmaceuticals announces the acquisition of two antibiotic products from Pfizer for the territories of Australia and New Zealand. The two injectable products, colistin and chloramphenicol are both essential treatments for serious infections. While the use of chloramphenicol is now highly restrictive due to the high incidence of serious side effects, it still has an important role in the treatment of highly resistant organisms.

Colistin is an essential treatment of serious gram-negative infections, particularly Pseudomonas aeruginosa.

In announcing the acquisition, Managing Director John Bacon commented “we are pleased to complete this acquisition with Pfizer’s regional office. Both products are a very good fit to our current range. Chloramphenicol is quite a low volume product but it’s maintenance on the market is critically important. Colistin is also an important antibiotic but in this case we believe it has some potential for growth.”